ADC Therapeutics SA (NYS:ADCT) set terms for its planned initial public offering on Monday, saying in a regulatory filing that it expects to offer 8.1 million shares priced at $23 to $26 each. The clinical-stage, oncology-focused biotech has applied to list on the New York Stock Exchange, under the ticker symbol "ADCT." Morgan Stanley, BofA Merrill Lynch and Cowen are underwriters on the deal, proceeds of which will be used to advance clinical trials and for R&D.
Sept. 23, 2019, 7:18 a.m. EDT
